BioXcel updates IGALMI at-home opportunity: up to 86M annual episodes, sNDA pending

BioXcel Therapeutics, Inc.

Updated market assessment for IGALMI at-home use identifies up to 86M addressable annual episodes, up from prior 57-77M estimate.
sNDA seeking FDA approval for at-home use submitted last month; assessment based on SERENITY At-Home study and market research.
Prescribers project using IGALMI in ~70% of schizophrenia/bipolar disorder patients; patients expect use in ~80% of agitation episodes.
Claims data: ~2.3M treated patients experience frequent acute agitation at home; up to 1.8M may be eligible for IGALMI.
Payers indicated expectations for broad formulary coverage with standard adjudication controls; prescribers report moderate-high unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.